肝硬化逆转及再代偿相关研究进展  

Research progress on cirrhosis reversal and recompensation

作　　者：徐京杭[1] 于岩岩[1] 徐小元[1] Xu Jinghang;Yu Yanyan;Xu Xiaoyuan(Department of Infectious Diseases,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院感染疾病科,北京100034

出　　处：《中华肝脏病杂志》2023年第7期673-676,共4页Chinese Journal of Hepatology

摘　　要：既往认为肝硬化(LC)病变不可逆,尤其进入失代偿期后病情逐渐加重,难以再回到代偿期。目前,越来越多证据显示病因治疗后部分患者LC逆转,控制病因和管理并发症后部分失代偿LC患者可再代偿。现从肝组织病理、肝功能和临床并发症这3个层面探讨LC逆转及再代偿相关的研究进展。Previously,liver lesions in cirrhosis were considered irreversible,especially because the condition aggravated gradually after entering the decompensated phase,thus making it difficult to return to the compensated phase.At present,more and more evidence shows that some patients with decompensated liver cirrhosis can be recompensated after the cause is controlled and complications are managed.This article explores the research progress related to LC reversal and recompensation from three aspects:liver histopathology,liver function,and clinical complications.

关 键 词：肝硬化 逆转 再代偿 

分 类 号：R575.2[医药卫生—消化系统]